COLUMBIA, S.C., Nov. 24 /PRNewswire-FirstCall/ -- Collexis Holdings Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today the formal launch of the Reviewer Finder product, an application which identifies the best reviewers based on their research profile. By using the proprietary Collexis Fingerprint technology, a submitted grant proposal or submitted scientific manuscript is analyzed and the resulting document Fingerprint is compared against more than 1.8 million expert Fingerprints -- simultaneously checking for conflicts of interest based on co-authorship and organizational affiliation.
The Collexis Reviewer Finder helps grant funding organizations in two very important ways: first it assists in reducing the time to identify the most qualified reviewers from hours to virtually minutes, secondly it enhances security by identifying reviewers with potential conflicts of interest by instantly analyzing over 30 million relationships between the research community and peer review community. The Reviewer Finder tool is the latest enhancement to the suite of Collexis grant management applications. These services provide funding organizations with sophisticated portfolio analysis tools to assist in identifying gaps and trends and track the success of their funding by an institution, department or researcher.
"We are very pleased to offer this new application to the scientific community as it will greatly enhance the efficiency in the publishing of scientific articles," says Christian Herzog, MD, managing director STM. "It helps funding organizations and peer reviewed journals to reduce the amount of time to identify the right reviewer but -- equally important -- to increase security that the chosen reviewer has no conflict of interest."
Customers like the National Institutes of Health (NIH), the world's largest funder of life-science research, and the Wellcome Trust, the largest independent medical research charity in the UK, utilize the Collexis solution to ensure the objectivity of their grant funding processes. The NHLBI as one of the largest NIH institutes has started to implement the Collexis Reviewer Finder to identify the best reviewers in a customized version.
About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of semantic search and
knowledge discovery software is headquartered in Columbia, South Carolina
(USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands
and Cologne, Germany. Collexis now offers the world's first pre-populated
scientific social network for life science researchers, www.biomedexperts.com.
Collexis' proprietary technology builds conceptual profiles of text, called
"Fingerprints", from documents, Websites, emails and other digitized content
and matches them with a comprehensive list of pre-defined "Fingerprinted"
concepts to make research results more relevant and efficient. This matching
of concepts eliminates the ambiguity and lack of priority associated with word
searches. The results are often described as "finding needles in many
haystacks." Through this novel approach, Collexis can build unique
applications to search, index and aggregate information as well as prioritize,
trend and predict data based on sources in multiple industries without the
limitations of language or dialect. Collexis' current clients in the public,
private and academic sectors include the Mayo Clinic;
Disclaimer: National Institutes of Health (NIH) is not considered a supporter or partner of Collexis.
Reference to NIH in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.
Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-KSB for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.
|SOURCE Collexis Holdings Inc.|
Copyright©2008 PR Newswire.
All rights reserved